Safety and Feasibility of Multiple Blood-brain Barrier Disruptions for the Treatment of Glioblastoma in Patients Undergoing Standard Adjuvant Chemotherapy
The neurosurgical research team led by Jin Woo Chang, MD, at Yonsei University College of Medicine in Seoul, Korea, is currently evaluating the safety and feasibility of using Insightec’s Exablate 4000 focused ultrasound system for repeated blood-brain barrier (BBB) opening in patients with glioblastoma undergoing chemotherapy.
The team has now enrolled, analyzed, and published data from six patients with 145 treatments in various regions of the brain. As this group continues to enroll up to 20 patients and collect follow-up data, they wonder whether BBB opening could be used with additional types of therapeutic agents that have previously been unable to reach these deadly tumors.
See the Journal of Neurosurgery >
Read more on ClinicalTrials.gov >